Literature DB >> 12071335

Suppression of immunoreactive macrophages in atheromatous lesions of rabbits by clodronate.

Ritva Ylitalo1, Heimo Syvälä, Pentti Tuohimaa, Pauli Ylitalo.   

Abstract

Bisphosphonates inhibit the development of experimental atherosclerosis and decrease the intima-media thickness of human carotid artery. Since arterial macrophages have a key role in atherogenesis, we studied whether clodronate, an antiatherogenic bisphosphonate, will suppress the appearance of macrophages generated by atheromatous process in the rabbit aorta. The atherosclerosis was caused in rabbits by means of a high-cholesterol (1%) diet, and the animals were treated simultaneously with saline (n = 11) or 25 mg/kg of clodronate disodium (n= 12) intravenously twice a week for 6 to 12 weeks. The cholesterol diet for 6 weeks caused no visible atheromatous plaques in the aorta, but feeding for 6 more weeks produced progressively atheromatous lesions. Immunohistochemistry with specific antimacrophage antibody showed an intensive accumulation of macrophages in the subendothelial layer of the aorta in cholesterol-fed rabbits treated with saline or clodronate for 6 weeks. In the aorta of rabbits treated with cholesterol diet + saline for 12 weeks, the area of immunoreactive macrophages extended from the internal elastic lamina up to the luminal surface of the aorta. However, far less immunoreactive macrophages were present in the atheromatous regions of the aorta of rabbits medicated with clodronate for 12 weeks; in the clodronate-treated animals the macrophages were located closer to the luminal surface of the aorta than in controls on saline. No atheromatous lesions and macrophages appeared in the aorta of rabbits on standard diet (n = 7). The results suggest that clodronate suppresses the appearance of cholesterol-phagocyting macrophages in arterial walls during atherogenesis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12071335     DOI: 10.1034/j.1600-0773.2002.900305.x

Source DB:  PubMed          Journal:  Pharmacol Toxicol        ISSN: 0901-9928


  7 in total

1.  Depletion of antigen-presenting cells by clodronate liposomes reverses the psoriatic skin phenotype in KC-Tie2 mice.

Authors:  N L Ward; C M Loyd; J A Wolfram; D Diaconu; C M Michaels; T S McCormick
Journal:  Br J Dermatol       Date:  2011-04       Impact factor: 9.302

2.  A population-based 2-year follow-up study on the relationship between bisphosphonates and the risk of stroke.

Authors:  J-H Kang; J J Keller; H-C Lin
Journal:  Osteoporos Int       Date:  2012-01-20       Impact factor: 4.507

3.  Differential effect of zoledronic acid on human vascular smooth muscle cells.

Authors:  Hassan Albadawi; Mounir J Haurani; Rahmi Oklu; Jordan P Trubiano; Peter J Laub; Hyung-Jin Yoo; Michael T Watkins
Journal:  J Surg Res       Date:  2012-11-08       Impact factor: 2.192

4.  Can clodronate be effective in the treatment of disabling hydroxyapatite crystal-deposition disease? A report of two cases.

Authors:  Gianantonio Saviola; Lul Abdi-Ali; Paola Baiardi; Maurizio Benucci
Journal:  Rheumatol Int       Date:  2010-07-28       Impact factor: 2.631

5.  Elimination of macrophages reduces glutaraldehyde-fixed porcine heart valve degeneration in mice subdermal model.

Authors:  Zongtao Liu; Yixuan Wang; Fei Xie; Xing Liu; Fei Li; Nianguo Dong
Journal:  Pharmacol Res Perspect       Date:  2021-02

6.  Macrophage depletion by free bisphosphonates and zoledronate-loaded red blood cells.

Authors:  Raffaella Sabatino; Antonella Antonelli; Serafina Battistelli; Reto Schwendener; Mauro Magnani; Luigia Rossi
Journal:  PLoS One       Date:  2014-06-26       Impact factor: 3.240

7.  Zoledronate upregulates MMP-9 and -13 in rat vascular smooth muscle cells by inducing oxidative stress.

Authors:  Mehmet Zuhuri Arun; Buket Reel; Graciela B Sala-Newby; Mark Bond; Aikaterini Tsaousi; Perry Maskell; Andrew C Newby
Journal:  Drug Des Devel Ther       Date:  2016-04-18       Impact factor: 4.162

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.